
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BDB018,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Eikon Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s BDB018, a novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8) being developed in advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : BDB018,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Eikon Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Details : The interim Phase 1 results show that intravenous administration of BDB001 as monotherapy is well-tolerated and induces robust immune activation resulting in clinical responses in solid tumors, including deep responses in anti-PD-(L)1 refractory tumors.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 09, 2020
